Selexys Pharmaceuticals Corporation

11 articles about Selexys Pharmaceuticals Corporation

• Novartis AG' $665 Million Bet Pays Off as Selexys Shows Off New Phase II Data

  12/5/2016

• Novartis AG Scoops Up U.S. Sickle Cell Drugmaker Selexys in $665 Million Deal

  11/22/2016

• Cytovance Biologics Inc. And Selexys Pharmaceuticals Corporation Announce Development And cGMP Manufacturing Agreement For SELK2 Drug Product

  5/6/2014

• Selexys Pharmaceuticals Corporation Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients With Pain Crises

  8/19/2013

• Cytovance Biologics Inc. Announces Manufacturing Agreement With Selexys Pharmaceuticals Corporation for Phase II Production of SelG1

  11/14/2012

• Selexys Pharmaceuticals Corporation Completes $23 Million Equity Financing and Signs Agreement With Novartis Pharmaceuticals Corporation for Up to $665 Million

  9/19/2012

• Selexys Pharmaceuticals Corporation Completes Phase I Clinical Study for Sickle Cell Drug

  12/19/2011

• Selexys Pharmaceuticals Corporation Initiates Enrollment in Phase I Clinical Study of SelG1

  5/4/2011

• Cytovance Biologics Awarded Biopharmaceutical Development and Manufacturing Contract by Selexys Pharmaceuticals Corporation

  4/26/2010

• Selexys Pharmaceuticals Corporation and Cytovance Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab)

  1/26/2009

• Selexys Pharmaceuticals Corporation Selects Cytovance Biologics for Process Development Services to Accelerate Development Programs

  8/1/2007